


HeartLung Technologies to Present Four Cutting-Edge Research Studies on AI-CAC™, AutoBMD™, and AI-CVD™ at RSNA 2024

HeartLung is the only AI company that is participating in RSNA 2024 both as a scientific presenter of multiple AI research studies and as an industry exhibitor

HOUSTON, TX, UNITED STATES,
November 30, 2024 /

EINPresswire.com/ -- HeartLung Technologies (www.heartlung.ai), a leading developer of innovative AI solutions for early detection of [heart disease](#), lung cancer, and other fatal conditions is pleased to announce that four of its scientific research studies on AI-CAC™, AutoBMD™, and AI-CVD™ have been accepted for presentation at the 2024 Radiological Society of North America (RSNA). The event, which is the largest gathering of doctors and other experts in the field of medical imaging, will be held December 1-4, 2024 in Chicago.



This exciting milestone is achieved shortly after HeartLung Technologies' seven research presentations at the 2024 Annual Scientific Sessions of the American Heart Association (AHA 2024) held November 16-18, and five research presentations at the 2024 Congress of European Society of Cardiology (ESC 2024).

"I'm pleased that our years of R&D at HeartLung is finally coming to fruition in patient care" said Dr. Morteza Naghavi, the founder and president of HeartLung Technologies who is also the lead author of the research studies presented at the RSNA 2024. "We're building the foundation for the future of AI-enabled early detection, monitoring, and prevention of fatal diseases such as heart disease, lung cancer, COPD, osteoporosis, steatosis and other deadly conditions that can

be averted”.

HeartLung’s cutting-edge research and innovations have the potential to significantly improve public health by preventing late-stage diseases that are often deadly and costly.

The following studies have been accepted for presentations:

HeartLung Presentation #1:

Session#: M2-SPCA

Session Title: Cardiac Imaging Monday Morning Poster Discussions

Presentation#: M2-SPCA-10

Abstract Title: AI-ENABLED CARDIAC CHAMBERS VOLUMETRY IN CORONARY ARTERY CALCIUM (CAC) SCANS (AI-CAC)

SIGNIFICANTLY IMPROVES ON AGATSTON CAC SCORE FOR PREDICTING ALL CARDIOVASCULAR

EVENTS: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS

Discussion Date/Time: 12/2/2024 9:00:00 AM-12/2/2024 9:30:00 AM



We’re building the foundation for the future of AI-enabled early detection and prevention of fatal diseases such as heart disease, lung cancer, COPD, osteoporosis, steatosis and other deadly diseases”

Dr. Morteza Naghavi, Founder and President of HeartLung Technologies

HeartLung Presentation #3:

Session#: M5A-SPCA

Session Title: Cardiac Imaging Monday Afternoon Poster Discussions I

HeartLung Presentation #2:


Session#: M5A-SPCA

Session Title: Cardiac Imaging Monday Afternoon Poster Discussions I

Presentation#: M5A-SPCA-3

Abstract Title: AI-ENABLED AUTOMATED BONE MINERAL DENSITY MEASUREMENT IN CORONARY ARTERY CALCIUM SCANS (AUTOBMD) IS ASSOCIATED WITH HIGH CORONARY ARTERY CALCIUM SCORE INDEPENDENTLY OF CONVENTIONAL RISK FACTORS: MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)

Discussion Date/Time: 12/2/2024 12:15:00 PM-12/2/2024 12:45:00 PM



AI-CAC with calcium score, calcified plaque characterization, and cardiac chambers volumes.

Presentation#: M5A-SPCA-1

Abstract Title: AUTOMATED LEFT VENTRICULAR VOLUMETRY USING ARTIFICIAL INTELLIGENCE IN CORONARY CALCIUM SCANS (AI-CAC) PREDICTS HEART FAILURE COMPARABLY TO CARDIAC MRI AND OUTPERFORMS NT-PROBNP: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Discussion Date/Time: 12/2/2024 12:15:00 PM-12/2/2024 12:45:00 PM

HeartLung Presentation #3:

Session#: M5A-SPCA

Session Title: Cardiac Imaging Monday Afternoon
Poster Discussions I


Presentation#: M5A-SPCA-2

Abstract Title: CORONARY ARTERY CALCIUM SCANS POWERED BY ARTIFICIAL INTELLIGENCE (AI-CAC) PREDICTS ATRIAL FIBRILLATION AND STROKE COMPARABLY TO CARDIAC MAGNETIC RESONANCE IMAGING: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)


Discussion Date/Time: 12/2/2024 12:15:00 PM-12/2/2024 12:45:00 PM

Every year RSNA's scientific review committee selects presentations through a rigorous peer-review process. The fact that HeartLung Technologies received acceptance for 4 research presentations speaks volume for the scientific power of HeartLung's outstanding team.

List of RSNA 2024 HeartLung Research Coauthors: Morteza Naghavi, MDa, Anthony P. Reeves, PhDb, Kyle Atlas, BSa, Chenyu Zhang, MSa, Thomas Atlas, MDc, Claudia Henschke, PhD., MDd, David Yankelevitz, MDd, Matthew J. Budoff, MDe, Dong Li, PhD, Wenjun Fan, MD, PhDm, Ruilin Yu, MPHn, Andrea Branch, MDd, Ning Ma, PhDd, Rowena Yip, PhDd, Sion K. Roy, MDe, Khurram Nasir, M.Df, Sabee Molloy, PhDg, Zahi Fayad, PhDf, Michael V. McConnell, MD, MSEEh, Ioannis Kakadiaris, MDi, Javier Zuelueta, MDd, David J. Maron, MDh, Jagat Narula, MD, PhDi, Prediman Shah, MDo, Kim Williams, MDj, Daniel Levy, M.Dk, Nathan D. Wong,



AutoChamber sample report



AutoBMD AI sample report with Z Score and T Score

PhD.

- a. HeartLung.AI, Houston, TX, 77021
- b. Department of Electrical and Computer Engineering, Cornell University, Ithaca, NY 14853
- c. Tustin Teleradiology, Tustin, CA 92780
- d. Mount Sinai Hospital, New York, NY 10029
- e. The Lundquist Institute, Torrance, CA 90502
- f. Houston Methodist Hospital, Houston, TX 77030
- g. Department of Radiology, University of California Irvine, CA 92697
- h. Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305
- i. The University of Texas Health Science Center at Houston, TX, 77030
- j. University of Louisville, Louisville, KY
- k. Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, 20824
- l. Heart Disease Prevention Program, Division of Cardiology, University of California Irvine, CA 92697
- m. Department of Epidemiology & Biostatistics, University of California Irvine, CA 92697
- n. Department of Epidemiology, University of California, Los Angeles, CA 90095
- o. Cedars-Sinai Medical Center, Los Angeles, CA, 90048



Dr. Morteza Naghavi, founder of HeartLung Technologies

About HeartLung Technologies

HeartLung Technologies aims to help people live long by eliminating preventable deaths caused by heart attacks, lung cancer, osteoporosis, chronic pulmonary obstructive disease (COPD), fatty liver disease, and other deadly medical conditions. HeartLung's team of industry-leading physicians and engineers are dedicated to increasing people's life-span and health-span by starting with taking out America's most deadly killers: heart disease and lung cancer. HeartLung is innovating for the millions of Americans and many more worldwide who can benefit from early detection of preventable fatal diseases. HeartLung.AI is a portfolio company of American Heart Technologies (AHT) founded by Dr. Morteza Naghavi, a leader in preventive cardiology and health-tech, former faculty of Texas Heart Institute and University of Texas in 2007. AHT was established as a vehicle for commercialization of innovative healthcare solutions, three of which received FDA approval and were commercialized under portfolio companies Endothelix Inc., and CardioNexus Corp, and HeartLung Corp.

For more information about HeartLung Technologies, please visit www.heartlung.ai. and www.americanhearttechnologies.com

Marlon Montes
HeartLung Corporation
+1 310-510-6004

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/765103686>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.